NHS Trials New Hope for Deadly Liver Disease

The NHS is poised to pilot a groundbreaking treatment for acute-on-chronic liver failure (ACLF), a condition rapidly increasing alongside global trends in obesity and alcohol-related liver disease. This isn’t just another clinical trial; it represents a potential paradigm shift in liver care, moving beyond the limited options of transplant or palliative care towards active recovery. The device, Dialive, offers a lifeline to a patient population facing a grim prognosis – a 70% mortality rate within 28 days – and signals a growing investment in innovative, organ-support technologies.

ACLF is a particularly insidious disease. Unlike chronic liver disease which develops over years, ACLF represents a sudden and catastrophic deterioration in liver function, often triggered by an acute insult like an infection or excessive alcohol consumption in someone with pre-existing liver damage. The rising rates of non-alcoholic fatty liver disease (NAFLD), directly linked to the obesity epidemic, are a major driver of this increase. Current treatment is largely supportive, focusing on managing complications and awaiting potential transplant eligibility – a solution hampered by organ shortages. The development of Dialive, a spinout from University College London, directly addresses this critical gap in care.

The Dialive device functions on principles similar to haemodialysis, but instead of filtering blood for kidney function, it targets dysfunctional albumin – a crucial protein produced by the liver. By removing this damaged protein and replacing it with a healthy version, Dialive aims to reduce inflammation and allow the liver to regenerate. The initial trial, involving 72 patients across 13 major hospitals, will be crucial in validating the promising results from a smaller 2023 study which showed ACLF reversal in 67% of treated patients compared to 33% in the standard care group.

The Forward Look: The success of this trial isn’t just about ACLF. It’s a bellwether for a broader trend: the development of ‘organ support’ technologies. We can expect to see increased investment in similar devices for other failing organs – particularly the lungs and kidneys – as healthcare systems grapple with aging populations and the rising incidence of chronic disease. However, several key hurdles remain. Scalability and cost-effectiveness will be paramount. If Dialive proves successful, the NHS will need to assess its ability to integrate this technology into existing infrastructure and ensure equitable access. Furthermore, Yaqrit, the company behind Dialive, will likely become an acquisition target for larger medical device companies, potentially accelerating its global rollout but also raising questions about pricing and accessibility. The data from this trial will be closely watched not only by clinicians but also by investors and policymakers alike, as it could redefine the future of liver disease management and pave the way for a new era of organ support therapies.